Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 362

1.

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.

Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM.

N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.

2.

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC; International Mepolizumab Study Group.

Am J Respir Crit Care Med. 2007 Dec 1;176(11):1062-71. Epub 2007 Sep 13.

PMID:
17872493
3.

Mepolizumab and exacerbations of refractory eosinophilic asthma.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.

N Engl J Med. 2009 Mar 5;360(10):973-84. doi: 10.1056/NEJMoa0808991. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

4.

Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma.

Dente FL, Bacci E, Bartoli ML, Cianchetti S, Costa F, Di Franco A, Malagrinò L, Vagaggini B, Paggiaro P.

Ann Allergy Asthma Immunol. 2010 Jun;104(6):464-70. doi: 10.1016/j.anai.2010.04.003.

PMID:
20568377
5.

Inhaled fluticasone propionate is effective as well as oral prednisone in reducing sputum eosinophilia during exacerbations of asthma which do not require hospitalization.

Di Franco A, Bacci E, Bartoli ML, Cianchetti S, Dente FL, Taccola M, Vagaggini B, Zingoni M, Paggiaro PL.

Pulm Pharmacol Ther. 2006;19(5):353-60. Epub 2005 Nov 11.

PMID:
16289980
6.

Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations.

Belda J, Margarit G, Martínez C, Bellido-Casado J, Casan P, Torrejón M, Brufal M, Rodríguez-Jerez F, Sanchis J.

Eur Respir J. 2007 Dec;30(6):1143-9. Epub 2007 Aug 9.

7.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group.

N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530.

8.

Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.

Liu Y, Zhang S, Li DW, Jiang SJ.

PLoS One. 2013;8(3):e59872. doi: 10.1371/journal.pone.0059872. Epub 2013 Mar 27. Erratum in: PLoS One. 2013;8(6). doi: 10.1371/annotation/8da4be4b-2de1-4c51-9c40-0f49dc212579.

9.

Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma.

Jayaram L, Duong M, Pizzichini MM, Pizzichini E, Kamada D, Efthimiadis A, Hargreave FE.

Eur Respir J. 2005 Jan;25(1):41-6.

10.

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS.

Am J Respir Crit Care Med. 2003 Jan 15;167(2):199-204. Epub 2002 Oct 17.

PMID:
12406833
11.

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER, Martin EC, Bugelski PJ, Herzyk DJ.

J Allergy Clin Immunol. 2001 Aug;108(2):250-7.

PMID:
11496242
12.

Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients.

Giannini D, Di Franco A, Cianchetti S, Bacci E, Dente FL, Vagaggini B, Paggiaro PL.

Clin Exp Allergy. 2000 Dec;30(12):1777-84.

PMID:
11122217
13.

Dupilumab in persistent asthma with elevated eosinophil levels.

Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G.

N Engl J Med. 2013 Jun 27;368(26):2455-66. doi: 10.1056/NEJMoa1304048. Epub 2013 May 21.

14.

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators.

N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.

16.

Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.

Sehmi R, Smith SG, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, Prazma CM, Ortega H, Martin JG, Nair P.

Clin Exp Allergy. 2016 Jun;46(6):793-802. doi: 10.1111/cea.12695.

PMID:
26685004
17.

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.

Allergy. 2005 Mar;60(3):309-16.

PMID:
15679715
18.
19.

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ.

N Engl J Med. 1999 Dec 23;341(26):1966-73.

20.

Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma.

van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ.

Thorax. 1999 May;54(5):403-8.

Supplemental Content

Support Center